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Abstract. Single nucleotide polymorphisms of TP53 gene in human populations are expected to cause  
perturbation of p53 function, and therefore could influence risk and/or progress of disease. There are dif-
ferences in inducing apoptosis, cell cycle arrest, transcriptional activity, protein interactions between vari-
ants in codon 72 (Arg72Pro), although the association of polymorphism and risk of cancer is controver-
sial. The aim of our study was to investigate the frequency of alleles and genotypes of Arg72Pro poly-
morphism in the ethnically homogenous Croatian population and to compare it with the worldwide popu-
lations. In a cohort of 576 participants the genotype frequencies of Arg/Arg, Arg/Pro and Pro/Pro  
are 54.34, 38.71 and 6.95 %, respectively. We statistically sorted the population of Croatia into  
the same group with other European populations and Caucasians from North America. This finding is  
important for the molecular pathways studies involved in disease as well as in pharmacogenetic studies. 
(doi: 10.5562/cca1866)  
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INTRODUCTION 
TP53 is a tumor suppressor gene that governs cellular 
responses to a broad spectrum of stress (DNA damage, 
hypoxia, oncogenic stress) by inducing cell cycle arrest, 
apoptosis or senescence and plays a key role in the pre-
vention of cancer development. Inactivation (mostly by 
mutations) of the p53 tumor suppressor is the single 
most common genetic defect in human cancer.1 
Variations in DNA sequence that have been found 
in unaffected human populations are considered as poly-
morphisms. Generally, variations in the DNA sequences 
can affect the development of disease and response to 
therapy and are thought to be key enablers in realizing 
the concept of personalized medicine. Eighty five vali-
dated polymorphisms are found in TP53, most of which 
the functional consequences are still not clarified. Only 
few p53 polymorphisms have been determined to alter 
its biochemical and/or biological function, and to ac-
complish the cancer risk in population studies. Among 
all known polymorphisms, the one causing an Arg72Pro 
substitution is the most extensively studied.2  
In human populations, codon 72 of TP53 has ei-
ther the sequence CCC (encodes for proline) or CGC 
(which encodes arginine). Arg72Pro is located within 
the proline-rich domain in exon 4 of TP53 gene.2,3 Alt-
hough both forms are considered as wild types and do 
not differ in the ability to bind to DNA, there are differ-
ences in mitochondrial localization, apoptosis, cell cycle 
progression, DNA repair, growth arrest and transcrip-
tional transactivation.2 However, it was found that this 
polymorphism may affect the mutant p53 binding abili-
ties and consequently functional properties of p73.4 
Arg72 increases the ability of p53 to bind the compo-
nents of the transcriptional machinery, to activate tran-
scription of target genes, to induce apoptosis, and to 
repress the transformation of primary cells.5 Unlike, 
Pro72 exhibits a lower apoptotic potential and causes an 
increased cellular arrest in G1 phase of the cell cycle.6–8 
This is an important gain-of-function polymorphism at 
the cellular level.  
These observations suggest that the p53 Arg72Pro 
polymorphism may influence the development of cancers 
which harbor wild-type p53 and possibly the ability of 
such tumors to respond to therapy and prognosis after 
cancer diagnosis, and longevity in general. However, the 
largest study of influence of Arg72Pro on cancer risk 
suggests that it is not associated with risk of cancer or any 
other disease but has effect on 5-year survival after can-
cer diagnosis and on general longevity.9 Pro/Pro homo-
zygote and Arg/Pro heterozygote increased survival after 
cancer diagnosis for 13 % and 9 %, respectively.9  
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The distribution of Arg72Pro polymorphism in 
the human population shows ethnic differences in 
allele expression.2,9–27 Whereas the Arg72Pro polymor-
phism is important for the tumor suppressor function 
of p53/p73 proteins, we investigated the genotypic 
frequency of p53 codon 72 polymorphism in the heal-
thy Croatian population, and compared the frequencies 
of Arg/Arg, Arg/Pro and Pro/Pro genotypes, as well as 
Arg and Pro alleles with the population of other coun-
tries worldwide.  
 
EXPERIMENTAL 
Participants 
The prospective study of Croatian population included 
576 (55 female, 521 male) unrelated individuals, ages 
24–69, the healthy blood donors from Croatian Institute 
of Transfusion Medicine, Zagreb. All participants gave 
written informed consent. The Ethics Committee of 
Croatian Institute of Transfusion Medicine, Zagreb, 
approved the research.  
 
Genotyping of p53 Arg72Pro 
Genomic DNA was isolated from peripheral leukocytes 
by salting out method.28 To identify TP53 codon 72 
polymorphisms the real-time PCR analysis for poly-
morphisms was performed using CFX96 Real-Time 
System (Bio Rad, Hercules, CA, USA) and TaqMan 
Pre-developed Assay Reagents for Allelic Discrimina-
tion C_2403545_10 (rs1042522) (Applied Biosystems, 
Foster City, CA, USA). For real-time PCR amplifica-
tion, the reaction volume was 10 µl. No-template con-
trols (NTC) and two positive controls (C/G) were run 
with each PCR reaction. The PCR reaction was carried 
out according to the manufacturer’s protocol.  
For allele discrimination, three clusters of points 
corresponding to the genotypes of GG, GC or CC are 
expected in the analyses. If there is fluorescence for the 
reporter from allele 1 (Fam), the specimen genotype is 
CC. If there is fluorescence for the reporter from allele 2 
(Vic) then the subject genotype is GG. If there is inter-
mediate fluorescence from both reporters the genotype 
is GC. If no fluorescence is reported for either dye, then 
the PCR reaction failed. 
Statistical Analysis 
The Mann-Whitney-Wilcoxon test was used to compare 
the genotype distribution between the results of our 
research in Croatia and results of other researches from 
countries around the globe. Confidence level of 99 % 
was used in statistical analysis. 
 
RESULTS 
p53 Codon 72 Polymorphisms in Croatia 
In cohort of 576 healthy controls from Croatian general 
population, we have shown the distribution of a well 
known functional polymorphism in TP53 gene. The data 
are summarized in Table 1. Forty (6.95 %) participants 
were Pro/Pro (C/C); 223 (38.71 %) were Pro/Arg (C/G), 
and 313 (54.34 %) were Arg/Arg homozygotes (G/G).  
To identify the possible gender-related differ-
ences, the Arg72Pro polymorphism was compared se-
parately in male and female participants within the Cro-
atian population. Among 55 women there are only 2 
(3.6 %) Pro homozygotes (C/C), 22 (40 %) Pro/Arg 
(C/G) heterozygotes, and 31 (56.4 %) Arg homozygotes 
(G/G); comparing to 38 (7.3 %) of 521 male subjects 
Pro homozygotes (C/C), 201 (38.6 %) Pro/Arg (C/G) 
heterozygotes, and 282 (54.1 %) Arg homozygotes 
(G/G) (Table 1). Since the distribution between genders 
is not equal (only 55 women out of 576 subjects) we 
were not able to do any statistical analysis.  
 
Statistical Analysis 
The aim of statistical analysis was to find "similarities" 
between populations of several countries worldwide and 
population of Croatia (Table 2). Therefore, we com-
pared results for Croatian population with results from 
each of the following studies: China, Japan, Turkey, 
Greece, Nigeria, South Africa, India, USA, United 
Kingdom, Netherlands, Denmark, Italy, Germany, Por-
tugal, Sweden and Slovakia. 
Null hypothesis for each comparison made was 
that two sets of results are drawn from the same popula-
tion (in a statistical sense) with confidence level 99 %. 
Verification of null hypothesis would mean that similar-
ities of Arg/Pro distribution between the populations (in 
Table 1. Distribution of p53 codon 72 polymorphism genotypes and allele frequencies in healthy participants in Croatia 
Participants 
Arg/Arg  Arg/Pro Pro/Pro Arg allele  Pro allele 
No. %  No. % No. % No. %  No. % 
Total (n=576) 313   54.34  223   38.71 40   6.95 849 74.7  303 26.3 
Female (n=55) 31 56.4  22     40 2 3.6 84 76.4  26 23.7 
Male (n=521) 282 54.1  201 38.6 38 7.3 765 73.4  27 26.6 
 
A. Zorić et al., TP53 Arg72Pro in Croatia 241 
Croat. Chem. Acta 85 (2012) 239. 
a biological sense) of countries in which the studies 
were made are too significant to be considered acci-
dental i.e. that it is worth looking into possible biologi-
cal reasons for similarities. 
According to obtained data, we divided the global 
population into two groups according to the "similarity" 
with Croatian population. The first "more similar" group 
consists mostly of European countries and Caucasian 
population of the USA. Only European populations of 
Greece and Turkey belong to another "more distinct" 
group together with Indian, Chinese and Japanese popu-
lations, as well as black population of Nigeria and South 
Africa.  
 
DISCUSSION 
Our study demonstrated the distribution of p53 poly-
morphism Arg72Pro in ethnically homogenous Cauca-
sians of Croatian origin. This is the first direct compari-
son of the Arg/Pro genotype frequencies in Croatian 
population with the population of Europe and the world. 
The solely study done earlier reported only frequency of 
heterozigosity (36.8 % of Arg/Pro genotype) using LOH 
method in 125 subjects.29 In our study we confirmed the 
same heterozigosity rate using real-time PCR analysis, 
but we also distinguished homozygotes, what is of im-
portance for further studies. 
Our results (54.34 % of Arg/Arg; 38.71 % of 
Arg/Pro; 6.95 % of Pro/Pro) are almost identical to 
Table 2. Statistical analysis of p53 codon 72 genotype in Croa-
tia compared to the results of studies of different countries 
 
n 
z(a) 
total Arg/Arg Arg/Pro Pro/Pro
USA(b) 308 168 112 28 0.19 
Denmark(b) 9.219 4.934 3.623 662 0.35 
UK(b) 250 142 93 15 0.62 
Netherlands(b) 158 91 58 9 0.69 
Italy(b) 140 83 47 10 0.83 
Germany(b) 193 114 66 13 0.94 
Portugal(b) 145 92 40 13 1.41 
Sweden(b) 188 89 83 16 1.49 
Slovakia(b) 330 200 113 17 1.67 
China(c) 45 10 26 9 4.01 
Japan(c) 442 178 210 54 4.24 
Turkey(c) 87 24 49 14 4.37 
Greece(c) 51 10 32 9 4.41 
Nigeria(c) 59 7 25 27 7.25 
India(c) 189 35 97 57 9.07 
S. Africa(c) 340 32 147 161 15.25
Croatia 576 313 223 40 – 
(a) Statistic for each research considered in statistical analysis. 
(b) From the value of z statistic, for these countries the null 
hypothesis is verified. 
(c) For these countries the null hypothesis is dismissed with 99 %
confidence. 
Table 3. Genotype and allele frequencies of p53 Arg72Pro polymorphism in different populations worldwide 
Country Total cases 
Arg/Arg Arg/Pro Pro/Pro Frequency 
No. % No. % No. % Arg alelle / % Pro alelle / % 
Croatia 576 313 54.34 223 38.71 40 6.95 74.7 26.3 
Turkey13 87 24 27.59 49 56.32 14 16.09 55.75 44.25 
Portugal18 145 92 63.45 40 27.59 13 8.97 77.24 22.76 
Greece14 51 10 19.61 32 62.75 9 17.65 50.98 49.02 
Italy22 140 86 61.43 47 33.57 7 5 78.21 21.79 
Sweden19 188 89 47.34 83 44.15 16 8.51 69.41 30.59 
Slovakia20 330 200 60.61 113 34.24 17 5.15 77.7 22.3 
Germany23 193 114 59.07 66 34.2 13 6.74 76.17 23.83 
Denmark9 9219 4934 53.52 3623 39.3 662 7.18 73.17 26.83 
UK21 250 142 56.8 93 37.2 15 6 75.4 24.6 
UK24 246 155 63 79 32 12 5 61.4 38.6 
USA27 308 168 54.55 112 36.36 28 9.09 72.73 27.27 
China(a) 45 10 22.22 26 57.78 9 20 51.11 49.89 
Japan(a) 44 18 40.91 16 36.36 10 22.73 59.09 49.91 
Nigeria(a) 59 7 11.86 25 42.37 27 45.76 33.05 66.95 
South Africa10 340 32 9 147 43 161 48 31 69 
India26 189 35 18.52 97 51.32 57 30.16 44.18 55.82 
Iran25 60 12 20 48 80 0 0 60 40 
(a) International HapMap Project. 
242 A. Zorić et al., TP53 Arg72Pro in Croatia 
Croat. Chem. Acta 85 (2012) 239. 
those reported for the Germany, Italy, Slovakia and 
other nearby countries, comparable in ethnicity and 
latitude.20,22,23 
Arg72Pro polymorphism of TP53 gene appears to 
be very informative anthropological marker with charac-
teristic ethnic pattern. Arg72Pro substitution has geno-
type frequencies in Europeans of ~60, 30 and 10 % for 
Arg/Arg, Arg/Pro and Pro/Pro, respectively.30 Cauca-
sians differ from other ethnic groups, particularly Afri-
cans and African Americans which have much higher 
frequency of Pro allele. In an early study by Weston et 
al. the significant difference between American Blacks 
and Whites was found: Pro allele was found in 61 % of 
African Americans comparing to 35 % of Caucasians.12 
This study was followed by few studies of Beckman et 
al.15,31 who showed a wide range variation of Pro allele 
from 17 % in Sweden population to 63 % in African 
Blacks in Nigeria. The majority of Caucasian individu-
als are carriers of the Arg allele. Generally, they claim 
the distribution of alleles differs from North to South. In 
favor to this premise is the study of the population of 
Southern Europe – in Turkey and Greece the Pro allele 
appears in more than 40 % of subjects,13,14 comparing to 
other European countries where it appears at much lower 
frequency (Table 3, 21–30 %). Significant ethnic differ-
ences in the Arg72Pro polymorphism may arise from a 
natural selection of a particular allele or from the influ-
ence of various environmental factors, such as sunlight.  
Polymorphism Arg72Pro was discovered as a dif-
ference in electrophoretic mobility of two versions of 
p53.32 There are significant functional differences be-
tween Arg and Pro allele. Arg allele of Arg72Pro poly-
morphism increases apoptosis, while Pro allele is con-
nected with decreased apoptosis but increased G1 cell 
cycle arrest.6,8  
Many studies were searching for involvement of 
Arg72Pro polymorphism in the risk of cancer including 
the risk of HPV-associated cancers, the prognosis of 
disease or response to therapy, longevity, hepatitis C and 
schizophrenia, in placental weight and in ageing.9,33–38 
Today, it seems that Arg72Pro does not influence the 
risk of cancer, but Pro allele definitely increases median 
survival and longevity.39 Øersted et al. have found in-
creased 5-year survival after diagnosis of cancer in 
persons carrying Pro allele.9 In a cohort of more than 
9000 participants was found that Arg/Pro and Pro/Pro 
versus Arg/Arg have reduced mortality, which could 
result from a generally decreased aging process caused 
by decreased proapoptotic activity and increased cell 
cycle–arresting abilities of p53. Thus, Pro allele might 
be a benefit for a person experiencing any critical ill-
ness.9 Some authors suggest considering Arg72Pro 
polymorphism in the context of other genetic variations 
such as mutations in p53 or other related genes.2 There-
by, only arginine expressing mutants in head and neck 
cancer patients caused poor response to chemotherapy 
and shorter survival.40  
The limitation of our study was that we did not 
have enough female subjects to statistically confirm the 
finding that there are no sex differences. Nevertheless 
we didn’t have equal distribution between genders to 
perform statistical analysis, there are no sex-related 
differences which was also reported previously.9 
The advantage is the size (576 subjects) and ho-
mogeneity of the population. The basis for reliable stud-
ies of SNP association with common diseases is the 
large representative control group. In the history many 
studies on claiming the importance of this SNP for the 
risk of cancer were irreproducible studies, done in small 
groups. Large prospective studies of the general popula-
tion are the gold-standard.39 
Human studies are necessary to predict the effects 
on humans. A careful matching of the participants for 
ethnicity, among other factors, should be done in the 
studies investigating complex molecular pathways in-
volved in carcinogenesis and other diseases as well as in 
pharmacogenetic studies. The large human studies, as 
the present study, are essential for modern and reliable 
biomedical research.  
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